explore -WSS

explore

author：leisure time 2025-09-27 13:10:46 - browse：27

Teladoc website -- health tech coverage from STAT — Adobe

Virtual care company Teladoc has a new chief executive officer following the abrupt departure of its longtime leader in April.

Chuck Divita, who took on the role Monday, previously led the commercial markets business at GuideWell, the parent company of health plan Florida Blue. He was also previously chief financial officer at FPIC Insurance Group, a publicly traded insurance company focused on medical liability.

Board chair David Snow said in a release that Divita’s health care experience and tenure at a public company made him an attractive candidate. Divita has also joined Teladoc’s board of directors.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

entertainment

WSS

Why depression after traumatic brain injury is distinct

Pushing for an NIH office for post

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Why depression after traumatic brain injury is distinct

Is there really a nursing shortage in the U.S.?

CZI to create biohub to build anti

focus

explore

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

leisure time

Sports medicine is finally prioritizing gender equality

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

In age of alternative facts, a scholarly course on calling out crap

Questions loom on AstraZeneca cancer drug as safety concerns ebb

United colonoscopy coverage change 'may cost lives,' doctors say

President Biden's budget: Here's what you might have missed

BioMarin wins approval for gene therapy to treat hemophilia A

How many hemophilia patients actually want gene therapy?

Novavax promises a turnaround & Lilly roils the obesity market

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

leisure time

How to save health care price transparency rules

Why depression after traumatic brain injury is distinct

Smaller biotechs seek to piggyback on weight loss drug boom

Readout Newsletter: Bristol, Sangamo, Gilead, and more

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Roche drug slashes death risk in early

leisure time

hotspot

entertainment

focus